E V Marietta1,2,3, A M Nadeau3, A K Cartee3, I Singh3, A Rishi3, R S Choung3, T-T Wu4, A Rubio-Tapia3, J A Murray1,3. 1. Department of Immunology, Mayo Clinic, Rochester, MN, USA. 2. Department of Dermatology, Mayo Clinic, Rochester, MN, USA. 3. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. 4. Department of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA.
Abstract
BACKGROUND: Olmesartan-associated enteropathy (OAE) is characterised by diarrhoea, nausea, vomiting, abdominal pain, weight loss and severe sprue-like enteropathy, all of which are resolved after discontinuation of olmesartan medoximil. AIM: To determine the mechanistic similarities of OAE with coeliac sprue. METHODS: Duodenal biopsies were extracted from OAE patients before (n = 11) or after (n = 17) discontinuation of olmesartan medoxomil (on or off olmesartan medoxomil). There were seven 'on/off' paired samples. Formalin-fixed biopsies were stained for CD8, CD4, FoxP3, IL-15R and psmad 2/3. Caco2 cells (human colonic epithelial line) were treated with olmesartan medoxomil and stained for IL-15, IL-15R and ZO-1. RESULTS: In the 'on olmesartan medoxomil' duodenal biopsies, a significant increase in the numbers of CD8+ cells and the number of cells that are FoxP3+ (a regulatory T-cell marker) are present in the duodenum as compared to the duodenal biopsies from patients who discontinued olmesartan medoxomil. IL15R expression is also increased with olmesartan medoxomil use. Evaluation of the effect of olmesartan medoxomil upon Caco-2 cells demonstrated that IL15 expression is increased in response to olmesartan medoxomil treatment. Further, ZO-1, a tight junction protein, is disrupted in olmesartan medoxomil-treated Caco-2 cells. CONCLUSIONS: Olmesartan-associated enteropathy shares many features with coeliac disease, including symptoms and immunopathogenic pathways, such as increased numbers of CD8+ cells and corresponding overexpression of IL15 by epithelial cells. Taken together, the treatment of epithelial cells with olmesartan medoxomil induces a response by intestinal epithelial cells that is similar to the innate effects of gluten upon the epithelium of coeliac patients.
BACKGROUND:Olmesartan-associated enteropathy (OAE) is characterised by diarrhoea, nausea, vomiting, abdominal pain, weight loss and severe sprue-like enteropathy, all of which are resolved after discontinuation of olmesartan medoximil. AIM: To determine the mechanistic similarities of OAE with coeliac sprue. METHODS: Duodenal biopsies were extracted from OAE patients before (n = 11) or after (n = 17) discontinuation of olmesartan medoxomil (on or off olmesartan medoxomil). There were seven 'on/off' paired samples. Formalin-fixed biopsies were stained for CD8, CD4, FoxP3, IL-15R and psmad 2/3. Caco2 cells (human colonic epithelial line) were treated with olmesartan medoxomil and stained for IL-15, IL-15R and ZO-1. RESULTS: In the 'on olmesartan medoxomil' duodenal biopsies, a significant increase in the numbers of CD8+ cells and the number of cells that are FoxP3+ (a regulatory T-cell marker) are present in the duodenum as compared to the duodenal biopsies from patients who discontinued olmesartan medoxomil. IL15R expression is also increased with olmesartan medoxomil use. Evaluation of the effect of olmesartan medoxomil upon Caco-2 cells demonstrated that IL15 expression is increased in response to olmesartan medoxomil treatment. Further, ZO-1, a tight junction protein, is disrupted in olmesartan medoxomil-treated Caco-2 cells. CONCLUSIONS:Olmesartan-associated enteropathy shares many features with coeliac disease, including symptoms and immunopathogenic pathways, such as increased numbers of CD8+ cells and corresponding overexpression of IL15 by epithelial cells. Taken together, the treatment of epithelial cells with olmesartan medoxomil induces a response by intestinal epithelial cells that is similar to the innate effects of gluten upon the epithelium of coeliac patients.
Authors: Sandro Drago; Ramzi El Asmar; Mariarosaria Di Pierro; Maria Grazia Clemente; Amit Tripathi; Anna Sapone; Manjusha Thakar; Giuseppe Iacono; Antonio Carroccio; Cinzia D'Agate; Tarcisio Not; Lucia Zampini; Carlo Catassi; Alessio Fasano Journal: Scand J Gastroenterol Date: 2006-04 Impact factor: 2.423
Authors: L Marthey; G Cadiot; P Seksik; P Pouderoux; J Lacroute; F Skinazi; B Mesnard; J A Chayvialle; G Savoye; A Druez; D Parlier; V Abitbol; M Gompel; M Eoche; E Poncin; R Bobichon; P Colardelle; P Wils; H Salloum; S Peschard; F Zerbib; B Méresse; N Cerf-Bensussan; G Malamut; F Carbonnel Journal: Aliment Pharmacol Ther Date: 2014-09-09 Impact factor: 8.171
Authors: Marisa DeGaetani; Christina A Tennyson; Benjamin Lebwohl; Suzanne K Lewis; Hussein Abu Daya; Carolina Arguelles-Grande; Govind Bhagat; Peter H R Green Journal: Am J Gastroenterol Date: 2013-05 Impact factor: 10.864
Authors: Michael Camilleri; Paula Carlson; Nelson Valentin; Andres Acosta; Jessica O'Neill; Deborah Eckert; Roy Dyer; Jie Na; Eric W Klee; Joseph A Murray Journal: Am J Physiol Gastrointest Liver Physiol Date: 2016-07-21 Impact factor: 4.052